- Home
- HFFG vs SKYE Comparison
HFFG vs SKYE Comparison
Compare HFFG & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HFFG
- SKYE
- Stock Information
- Founded
- HFFG N/A
- SKYE 2012
- Country
- HFFG United States
- SKYE United States
- Employees
- HFFG N/A
- SKYE N/A
- Industry
- HFFG Food Distributors
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- HFFG Consumer Discretionary
- SKYE Health Care
- Exchange
- HFFG Nasdaq
- SKYE Nasdaq
- Market Cap
- HFFG 162.4M
- SKYE 172.9M
- IPO Year
- HFFG N/A
- SKYE N/A
- Fundamental
- Price
- HFFG $3.27
- SKYE $3.14
- Analyst Decision
- HFFG
- SKYE Strong Buy
- Analyst Count
- HFFG 0
- SKYE 5
- Target Price
- HFFG N/A
- SKYE $18.40
- AVG Volume (30 Days)
- HFFG 39.9K
- SKYE 346.3K
- Earning Date
- HFFG 11-07-2024
- SKYE 11-09-2024
- Dividend Yield
- HFFG N/A
- SKYE N/A
- EPS Growth
- HFFG N/A
- SKYE N/A
- EPS
- HFFG 0.07
- SKYE N/A
- Revenue
- HFFG $1,160,322,000.00
- SKYE N/A
- Revenue This Year
- HFFG N/A
- SKYE N/A
- Revenue Next Year
- HFFG N/A
- SKYE N/A
- P/E Ratio
- HFFG $46.72
- SKYE N/A
- Revenue Growth
- HFFG N/A
- SKYE N/A
- 52 Week Low
- HFFG $2.46
- SKYE $1.44
- 52 Week High
- HFFG $5.91
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- HFFG 48.84
- SKYE 29.03
- Support Level
- HFFG $3.38
- SKYE $5.03
- Resistance Level
- HFFG $3.72
- SKYE $5.89
- Average True Range (ATR)
- HFFG 0.21
- SKYE 0.60
- MACD
- HFFG 0.02
- SKYE -0.23
- Stochastic Oscillator
- HFFG 35.71
- SKYE 4.57
About HFFG HF Foods Group Inc.
HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, seafood, frozen and dry food, and non-food products to Asian restaurants and other food service customers throughout the United States. The Company's business consists of one operating segment; HF Group, which operates solely in the United States. The Company's customer base consists of Chinese and Asian restaurants, and it provides sales and service support to customers who mainly converse in Mandarin or Chinese dialects.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.